Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Subbiah V.Hu M.I.Wirth L.J.Schuler M.Mansfield A.S.Curigliano G.Brose M.S.Zhu V.W.Leboulleux S.Bowles D.W.Baik C.S.Adkins D.Keam B.Matos I.Garralda E.Gainor J.F.Lopes G.CHIA-CHI LINGodbert Y.Sarker D.Miller S.G.Clifford C.Zhang H.Turner C.D.Taylor M.H.2022-09-152022-09-1520212213-8587https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110739461&doi=10.1016%2fS2213-8587%2821%2900120-0&partnerID=40&md5=7919ecd0394f9f4da7604f5d5238dfb6https://scholars.lib.ntu.edu.tw/handle/123456789/620215[SDGs]SDG3Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyjournal article10.1016/S2213-8587(21)00120-0341181982-s2.0-85110739461